Therapeutic Advances in Hematology

Papers
(The H4-Index of Therapeutic Advances in Hematology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents38
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine32
Prognostic impact of IL7R mutations on acute myeloid leukemia32
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study29
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy23
Brain iron content and cognitive function in patients with β-thalassemia19
Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis18
Efficacy and safety of Busulfan–Fludarabine versus Busulfan–Cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: a meta-analysis o18
Treatment of multiple myeloma: What is the impact on T-cell function?16
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors16
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia14
Macrofocal multiple myeloma in the era of novel agents in China14
Role of abatacept in the prevention of graft- versus -host disease: current perspectives13
0.053925037384033